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Horse immunization with short-chain consensus
α-neurotoxin generates antibodies against broad
spectrum of elapid venomous species
Guillermo de la Rosa 1,2, Felipe Olvera1, Irving G. Archundia1, Bruno Lomonte 3, Alejandro Alagón1 &
Gerardo Corzo 1
Antivenoms are fundamental in the therapy for snakebites. In elapid venoms, there are toxins,
e.g. short-chain α-neurotoxins, which are quite abundant, highly toxic, and consequently play
a major role in envenomation processes. The core problem is that such α-neurotoxins are
weakly immunogenic, and many current elapid antivenoms show low reactivity towards them.
We have previously developed a recombinant consensus short-chain α-neurotoxin (ScNtx)
based on sequences from the most lethal elapid venoms from America, Africa, Asia, and
Oceania. Here we report that an antivenom generated by immunizing horses with ScNtx can
successfully neutralize the lethality of pure recombinant and native short-chain α-neuro-
toxins, as well as whole neurotoxic elapid venoms from diverse genera such as Micrurus,
Dendroaspis, Naja, Walterinnesia, Ophiophagus and Hydrophis. These results provide a proof-of-
principle for using recombinant proteins with rationally designed consensus sequences as
universal immunogens for developing next-generation antivenoms with higher effectiveness
and broader neutralizing capacity.
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Snakebite is one the most neglected diseases, especially in thepoorest tropical countries near the Equator. Literatureanalysis based on statistical estimates shows that up to 5.5
million snakebites could occur every year, yielding to more than
100,000 deaths worldwide1. The only venom-speciﬁc life-saving
treatment proved as effective and recommended by the World
Health Organization (WHO) is the timely parenteral application
of snake antivenom2. Essentially, the active principle of anti-
venoms is a polyclonal mixture of immunoglobulins, or frag-
ments thereof, like Fab or F(ab′)2. These are typically derived
from the sera of hyper-immunized animals, mainly horses, and
are able to neutralize the different venom toxins to prevent their
deleterious effects3.
In antivenom design and production, venoms from snakes
responsible for causing high morbidity and mortality are com-
monly selected as immunogens3. In compliance with the host
immune system, both toxic and non-toxic venom components
elicit an antibody response; as a result, antivenoms contain col-
lections of antibodies against both relevant and non-relevant
components, which can affect antivenom efﬁcacy. Postsynaptic α-
neurotoxins are one of the main toxic elements in elapid venoms
and the most poorly recognized components by current anti-
venoms4–6, despite being rather abundant protein components in
venoms used as immunogens.
α-Neurotoxins are classiﬁed as type I (short-chain), type II
(long-chain), and non-conventional neurotoxins7. Short-chain α-
neurotoxins (60–62 amino acids) have been associated with the
high toxicity of many elapid venoms. They bind to the nicotinic
acetylcholine receptors (nAChR) blocking neurotransmitter
binding. Accordingly, they cause non-depolarizing blockade and
consequently abolish neurotransmission, resembling curare-
mimetic effects8. Under an elapid snakebite scenario, therefore,
an effective anti-elapid therapy should have a collection of IgGs, F
(ab′)2, or Fab fragments able to properly neutralize α-neurotoxins
in order to prevent or reverse postsynaptic neurotoxicity caused
by these curare-mimetic toxins9.
Aiming to develop complementary strategies to improve the
antibody response and cross-recognition towards short-chain α-
neurotoxins, our previous work focused on the design, recombi-
nant expression, and biochemical characterization of a consensus
type I α-neurotoxin with generic traits, here called ScNtx10. In
this study, the ScNtx is used as an immunogen in horses, which
are the preferred animal used for production of snake antivenoms
available on the market worldwide. The resulting anti-ScNtx
experimental antivenom (EAv) efﬁcacy and species coverage,
expressed as median effective dose (ED50), are systematically
evaluated. Thus, our goal is to determine the extent of protection
provided by this antivenom in mouse lethality tests against the
challenge of isolated recombinant type I neurotoxins, as a proof
of concept, and also against whole elapid venoms from snakes
considered of highest medical importance in the Americas,
Africa, Asia, and Oceania. Our results strongly suggest that a
consensus α-neurotoxin as a rational-based immunogen in the
production of antivenoms against neurotoxic elapid venoms
could result in a product with a wide spectrum of speciﬁcity,
efﬁcacy, and affordability.
Results
ScNtx as immunogen. In order to better understand the role of
type I α-neurotoxins within the overall lethality of whole elapid
venoms, we developed a horse-derived antivenom using a bio-
logically active type I consensus α-neurotoxin, ScNtx, as a “uni-
versal” immunogen. The ScNtx was designed to show better
antigenic properties (high therapeutic antibody titers) and thus to
produce better antivenoms. We found that the group of three
horses, immunized in a multi-site manner with increasing ScNtx
doses (from 10 to 400 µg), produced antibodies that recognized
the homologous immunogen in enzyme-linked immunosorbent
assay (ELISA). Serum analysis shows that the response was rising
over 210 days, meaning that increasing doses of ScNtx were
efﬁcient in inducing antibody production in these large animals.
The titer of antibodies had a tendency to increase in response to
repeated injections of the neurotoxin; nonetheless, ScNtx evoked
a different response in the three animals (Fig. 1), one of them
reaching a titer as high as 18,000.
Lethal potencies. The efﬁcient assessment of antivenoms (ED50)
is based on their ability to neutralize the lethal effect of snake
venoms (lethal dose, 50% (LD50)). Therefore, we ﬁrst determined
the LD50 for all toxins and venoms studied in this work (Table 1).
In total, we used 4 short-chain α-neurotoxins and 29 elapid snake
venoms from species distributed in different world regions. The
short-chain α-neurotoxins had intravenous (IV) LD50s ranging
from 1.2 to 19.0 µg/mouse. Concerning the elapid venoms, those
from the Micrurus genus had LD50s ranging from 3.8 µg/mouse
(Micrurus browni) to 15.0 µg/mouse (Micrurus tener tener);
venoms from Dendroaspis ranged from 5.3 to 17.0 µg/mouse; the
LD50s of the venoms from Naja genus were from 0.9 (Naja haje
from Morocco) to 22.7 µg/mouse (Naja mossambica); venoms
from Pseudechis were from 6.9 to 8.9 µg/mouse, and ﬁnally, the
LD50s of venoms from Ophiophagus hannah, Walterinnesia
aegyptia, Oxyuranus scutellatus, and sea snake Hydrophis (Pela-
mis) platura were 11.5, 4.9, 0.7, and 3.9 µg/mouse, respectively.
ScNtx elicits neutralizing antisera. First, we assessed the indi-
vidual response and maturation of the immune response based on
the neutralization potency of three serum samples collected
throughout the immunization period of the horses, correspond-
ing to days 98, 147, and 206. Results presented in Fig. 2 revealed
that animals exhibited differences in neutralization potency
against α-neurotoxins. In general, effective doses (ED50) were
higher in samples from day 98 and lower from day 206, indicating
an increase in neutralizing potency over time.
Second, we developed two lots of EAvs called Lot #1 and Lot
#2. Lot #1 contains antibodies from sera pooled from horse 2 at
days 147 and 205, and Lot #2 has antibodies from the day 708.
Both lots have a protein content of 50 mg/mL. Lot #1 was
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Fig. 1 Time course of the speciﬁc antibody response of horses against the
consensus short-chain α-neurotoxin (ScNtx). Horse hyperimmune sera
raised against the ScNtx were titrated by enzyme-linked immunosorbent
assay (ELISA). Dashed lines indicate samples used for neutralization tests,
corresponding to days 98 (blue), 147 (red), and 205 (orange) of the
immunization. Points represent mean ± SD of triplicate wells of the ELISA
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comprehensively evaluated, while Lot #2 was used only used for
some venoms.
ScNtx antivenom. The vast array of pathophysiological symp-
toms exhibited by elapid envenomation are related to pre-
synaptic- and postsynaptic-acting toxins. Venomics and
conventional research have unveiled many predominant pre-
synaptic and predominant postsynaptic elapid venoms. Thus, we
aimed to assess the extent of protection of our EAv against short-
chain α-neurotoxins and well-known elapid venoms from the
Americas, Africa, Asia, and Oceania.
Efﬁcacy of ScNtx antivenom against puriﬁed α-neurotoxins.
The EAv Lot #1 neutralized the lethal effect of puriﬁed type I α-
neurotoxins. The ED50 values determined for this preparation,
against α-neurotoxins, are expressed in µL/mouse and listed in
Table 1. This anti-ScNtx preparation neutralized the lethality of
all the puriﬁed α-neurotoxins, with ED50 values around 40 µL/
mouse. EAv had an ED50= 49.1 μL/mouse against the ScNtx,
meaning 230 μg of ScNtx neutralized by 1 mL/EAv or 230 μg of
toxin/50 mg of immunoglobulins. Lot #2 had a similar range of
potency. Similarly, as shown in Table 1, EAv Lot #1 had an ED50
= 45.1 μL/mouse (1.2 mg/mL EAv) and ED50= 31.7 μL/mouse
(280 μg/mL EAv) against recombinant MlatA1 and r.D.H,
Table 1 Median LD50 and ED50 values of α-neurotoxins or elapid venoms, as well as median values of antivenom (EAv)
α-Neurotoxin/
venom
LD50 in µg/mice
(95% CI)
Horse EAv ED50
(µL/mice) (95%
CI), Lot #1
Horse EAv ED50
(µL/mice) (95%
CI), Lot #2
Average mg toxin
or venom/mL EAv
Average LD50 of
toxin or venom/
mL EAv
α-Neurotoxins
ScNtx 3.9 (3.8–3.9) 49.1 (47.8–50.4) 40–45 0.23 61.1
MlatA1 19 (18–20) 45.4 (44.1–46.8) ND 1.25 66.1
r.D.H 3 (2.8–3.2) 31.7 (31.7–31.8) ND 0.28 94.6
P01424a 1.2 (1.1–1.3) 34.3 (33.7–34.9) ND 0.17 145.7
Venoms
Micrurus browni 3.8 (3.5–4.1) NN ND – –
Micrurus diastema 6 (5.5–6.5) 191.5 (188.7–194.3) NN 0.09 15.6
Micrurus distans 12 (10–14) NN ND – –
Micrurus fulvius 4 (3.8–4.2) NN ND – –
Micrurus
laticorallis
10 (9.1–11.4) 171.1 (166.0–175.0) NN 0.17 17.5
Micrurus
nigrocinctus
7 (5–9) 56.5 (54.8–58.1) NN 0.37 53.1
Micrurus
surinamensis
10 (9.5–10.5) 51.2 (49.7–52.7) 25.6 (20.0–30.0) 0.78 78.1
Micrurus tener
tener
15 (13–17) NN ND – –
Dendroaspis
angusticeps
17 (16–18) 178.0 (171.3–185.4) NN 0.28 16.8
Dendroaspis
polylepis
5.3 (5–5.5) 149.1 (141.2–157.3) NN 0.16 20.1
Dendroaspis viridis 12 (11.9–12.2) NN ND – –
Naja atra 8 (7.7–8.2) 37.5 (35.5–39.5) 34.2 (28.5–41.1) 0.67 83.0
Naja hajea 0.9 (0.8–1) 77.4 (76.6–78.2) 72.9 (63.9–81.0) 0.04 40.0
Naja kaouthia 3.9 (3.7–4.2) 50.0 (47.0–53.0) >400 0.23 60.0
Naja katiensis 20.5 (18.4–22.7) ND >400 – –
Naja oxiana 8 (7.0–9.8) ND 24.1 (20.1–28.5) 0.99b 124.4b
Naja melanoleuca 6.5 (6.4–6.6) 72.3 (69.9–74.7) 306.0 (301.0–311.0) 0.11 15.8
Naja mossambica 22.7 (19.5–25.8) NN NN – –
Naja naja naja 9.4 (9.3–9.6) 65.5 (63.1–67.7) ND 0.43 45.8
Naja nigricollis 18 (17–19) NN ND – –
Naja nivea 8.2 (8–8.4) 25 (20–30) 106.0 (92.5–121.5) 0.38 46.7
Naja nubiae 8.3 (8.1–8.4) 173.7 (169.1–178.4) ND 0.14 17.3
Naja pallida 17 (17.8–17.2) NN ND – –
Ophiophagus
hannah
11.5 (10.9–12.2) 47.9 (44.1–52.1) 74.9 (73.2–76.7) 0.56 48.8
Hydrophis platura 3.9 (0.8–6.4)c 40–66 ND No <0.17 No <45.4
Walterinnesia
aegyptia
4.9 (3.9–5.8) 55.7 (53.1–58.5) 44.5 (40.0–49.5) 0.29 59.8
Oxyuranus
scutellatus
0.7 (0.6–0.8) ND NN – –
Pseudechis
australis
6.9 (5.6–8.6) ND NN – –
Pseudechis colleti 8.9 (8.4–9.5) ND NN – –
Lot #1 and Lot #2 have a protein content of 50mg/mL; for Lot #2 >400 denotes that neutralization was found but no 100% of survival
95% CI 95% conﬁdence intervals (shown within parentheses), ED50 median effective dose, LD50 lethal dose, EAv experimental antivirus, NN no neutralization at a maximum level of 200 µL/mouse for Lot
#1, and 400 µL for Lot #2 (100% lethality), ND not determined
a5 × LD50 were used for ED50 determination in this case. All other values were obtained with a venom challenge of 3 × LD50
bBased on Lot #2
cValue obtained from ref. 45
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respectively, and an ED50= 34.3 μL/mouse (170 μg/mL EAv)
against the native type I α-neurotoxin, P01424.
Efﬁcacy of ScNtx antivenom against coral snake venoms.
Micrurus fulvius,M. tener,M. browni, andM. distans whole venoms
are not neutralized by the EAv (efﬁcient against type I α-neuro-
toxins). On the other hand, EAv Lot #1 neutralized M. laticollaris
(ED50= 171.0 μL/mouse) and M. diastema (ED50= 191.0 μL/
mouse) venoms with higher doses. That means that 170 and 90 μg
of each venom is neutralized by 1mL of EAv (50mg). Nonetheless,
venoms from these species but obtained from different individuals
were not neutralized by Lot #2. Similar ﬁndings were determined
for the Central American coral snake Micrurus nigrocinctus. On the
one hand, EAv Lot #1 was able to successfully neutralize its lethality
(ED50= 56.6 μL/mouse). On the other hand, EAv Lot #2 did not
neutralize the lethality of a different individual. Finally, for M.
surinamensis both lots of EAv were highly efﬁcient in neutralizing
the lethality of the venom from the same individual snake (ED50=
51.6 and 25.6 μL/mouse, respectively) (Table 1).
Efﬁcacy of ScNtx antivenom against cobra venoms. To deter-
mine the efﬁcacy of the EAv on more complex elapid venoms, we
performed neutralization assays on 13 different species of spitting
and non-spitting cobras. In our ﬁndings, the lethality of venoms
of the spitting cobras Naja nigricollis, N. pallida, N. katiensis, and
N. mossambica was not abolished by the EAv, unlike the N.
nubiae venom (ED50= 173 μL/mouse) (Table 1). We next
addressed whether the EAv was effective against the non-spitting
cobras. As a ﬁrst ﬁnding, our data indicated that non-spitting
cobras (Naja) show, in most cases, the most lethal venoms. We
also found that they are the best neutralized by the EAv here
characterized. For example, the N. haje venom used in this work
had a LD50= 0.9 μg/mouse, and its lethality was inhibited by the
EAv Lot #1 (ED50= 77.4 μL/mouse). Similar efﬁcacy was found
for the venoms from N. melanoleuca (ED50= 72.4 μL/mouse) and
N. naja (ED50= 65.5 μL/mouse).
Discussion
Snake venoms are an exquisite panoply of molecules, mostly
proteins, contributing differentially in the pathophysiological
effects in snakebites. Nonetheless, such complexity is expressed as
a relatively small but important set of clinical manifestations,
such as ﬂaccid paralysis, local tissue damage, systemic myolysis,
hemorrhage, and coagulation alterations, among others. For
efﬁcient immunotherapy against snakebite envenoming, proper
neutralization of toxins playing important roles is required11. A
key set of potential targets are the elapid α-neurotoxins, which
cause ﬂaccid paralysis leading to death by respiratory failure.
However, one of the main drawbacks related to α-neurotoxins is
their poor immunogenicity. Additionally, many works have
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Fig. 2 Neutralization potencies, plotted as median effective dose (ED50). Serum samples were obtained from individual horses immunized with the
consensus short-chain α-neurotoxin (ScNtx) at days 98, 147, and 205. ED50 values are expressed in µL/mouse (volume of anti-ScNtx able to neutralize 3 ×
LD50 (lethal dose, 50%) of puriﬁed short-chain neurotoxins ScNtx, MlatA1 or rD.H.). Values were estimated in groups of ﬁve mice, injected by the
intravenous route. Error bars represent the 95% conﬁdence limits for the ED50 value. The data obtained from the groups of “Horse” and “Day” of
immunization were analyzed statistically by two-way analysis of variance (ANOVA) followed by paired Student’s t test. A p value of <0.05 was considered
signiﬁcant, as indicated by *. Horse 2 produces antibodies with the best neutralization potencies from after the 147th day of immunization
Toxin Amino acid sequence Identity(%)
Accession
#
ScNtx 100
rD.H 85
MlatA1 84
P01426 83
P80548 81
Atratoxin 79
MS1 79
P01424 77
Pelamitoxin 75
W-III 73
P86420
K9MCH1
P01426
P80548
AAR33036
P86095
P01424
P62388
C1IC47
Loop I Loop II Loop III
Fig. 3 Multiple sequence alignment of the most lethal short-chain α-neurotoxins. ScNtx: Synthetic consensus α-neurotoxin10; rD.H: Micrurus diastema
(recombinant)53; MlatA1: Micrurus laticollaris (recombinant)52; P01426: Naja spp.; P80548: Micrurus nigrocinctus4; Atratoxin: Naja atra; MS1: Micrurus
surinamensis; P01424: Naja melanoleuca; pelamitoxin: Hydrophis platura; W-III: Walterinnesia aegyptia. Differences from the ScNtx are indicated by bold
letters; cysteines and disulﬁde bridge arrangements are colored in blue
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suggested the role of type I α-neurotoxins in the lethal potency of
venoms stemming from α-neurotoxins’ high toxicity, molecular
action, and abundance5,12.
Overall, the efﬁcacy of the experimental antivenom (ScNtx
antivenom) correlates with the presence of type I α-neurotoxins
and some other members of the 3FTx family within the venoms.
First, the neutralization of pure α-neurotoxins by the EAv suggest
shared immunogenic determinants among these toxins. In fact,
comparing their amino acid sequences, shown in Fig. 3, we
qualitatively deduced a high conservation in two regions: from
the ﬁrst to the third cysteine (ﬁrst loop) and from the second to
the fourth cysteine (Cys) residue, which bears the region corre-
sponding to the second loop. The latter, particularly, contains the
amino acid residues involved in the toxin–receptor interaction.
As expected, the conservation of some residues at the second loop
among the ScNtx sequence and other 3FTxs such as fasciculins13
and long-chain neurotoxins13–15 agrees with the conclusion of
some researchers that postulates this region as a conserved neu-
tralization epitope on α-neurotoxins16. Henceforth, in-depth
studies on mapping the interactions of ScNtx with its elicited
horse antibodies would be revealing to this hypothesis.
Micrurus produces potent neurotoxic venoms that act on the
neuromuscular junction. It has been demonstrated that there are
two main protein families among them: phospholipases A2
(PLA2s) and three-ﬁnger toxins (3FTxs). In a global view, the
proportion of PLA2s vs. 3FTxs varies among North American and
South American species17. For instance, venoms from M. fulvius
(Florida) and M. tener (Texas) are PLA2 predominant, while M.
surinamensis (South America) contains a 3FTx-rich venom
almost devoid of PLA2 activity. For the former, it has been
demonstrated that such PLA2s are the main lethal components in
the mouse model of envenomation18. In the case of M. nigro-
cinctus (Central America), which contains a venom that is PLA2
predominant over 3FTxs4, EAv was able to successfully neutralize
its lethality (ED50= 56.6 μL/mouse) and had similar efﬁcacy to
some commercial antivenoms ranging from 63 to 123 μL/mouse
(Coralmyn® and anti-Micrurus, respectively)19. We conclude that
the α-neurotoxin fraction is highly relevant for its lethality. In this
case such effect could be led by the main short-chain α-
neurotoxin P80548, which presents 81% identity compared to the
ScNtx, as shown in Fig. 3, which is also the most lethal toxin in
this venom4. Similarly, both the EAv Lot #1 and Lot #2 were
highly efﬁcient in neutralizing the lethality of M. surinamensis
(3FTx-rich venom) venom, which contains a large arsenal of α-
neurotoxins that shares high identity in sequence to ScNtx (>74%,
Fig. 3)20.
The EAv is efﬁcient against 3FTx-rich cobra (Naja) venoms.
Cobra venoms contain 3FTxs, PLA2s, metalloproteinases
(SVMPs), Cys-rich secretory proteins, and L-amino oxidases
(LAAOs)21,22 as principal protein families. Notwithstanding this
set of toxins, most human envenomations result in neurological
affectations and in some cases serious local injuries, which cor-
relate with the predominance of 3FTxs, SVMPs, or PLA2s. For
instance, N. nigricollis, N. katiensis, N. pallida, and N. mossambica
are rich in cytotoxins/cardiotoxins, primarily, followed by PLA2s
and metalloproteinases. These toxins cause local tissue necrosis
and hemorrhage; therefore, the inefﬁcacy of our EAv on these
venoms agrees with their proteomics and distinctive clinical
manifestation22,23. On the other hand, the EAv does neutralize
3FTx-predominant cobra venoms such as N. nubiae (type I
neurotoxin content ~12.6%22), N. haje (3FTx= ~60%)24,25, N.
melanoleuca (3FTx= ~57%)25,26—one possible target could be
the α-neurotoxin P01424 (LD50= 0.9 μg/mouse) that greatly
inﬂuences its lethality and that we showed is neutralized by the
EAv—N. naja (3FTx= ~63.8%)27—which is one of the main
species responsible for snakebite mortality in South-Asia—and
Naja oxiana (type I neurotoxin content >12%)28. The present
study has only investigated the neutralization of the venom/toxin-
induced lethality. Consequently, this work clearly has some lim-
itations. The most important lies in the fact that we cannot
demonstrate whether EAv cross-reacts with other 3FTxs, such as
type II, and cytotoxin/cardiotoxins. However, our results indicate
that cross-reaction might occur. For instance, antibodies to ScNtx
in the EAv were able to protect from lethal doses of the venoms
from N. atra, N. nivea, and N. kaouthia (3FTx= 56–78%), which
are not only rich in cytotoxins (e.g., CTX)29–31 but also in type II
α-neurotoxins (e.g., α-cobratoxin P0139)21–32. It is well known
that N. atra venom produces cytotoxicity resulting from the
action of the group of toxins historically known as CTX29,31, and
likewise produces neurotoxicity caused mainly by type I α-
neurotoxins (e.g., atratoxins) and muscarinic toxins (MTs), which
are also considered to play important roles in the envenoming
process. Naja nivea venom, in turn, displays important myotoxic,
cardiotoxic, and neurotoxic activities31. These results reveal as a
whole the speciﬁc role of type I α-neurotoxins vs. other toxic
elements on the lethality of these venoms and an arguable cross-
reactivity among other 3FTxs.
To test the role of a likely cross-reactivity among 3FTxs, we
used the venom of Mambas. They produce venoms that contain a
rich cocktail of rapid-acting neurotoxins32. Human envenoma-
tion by mambas can lead to neurotoxicity with no reports of local
tissue damage8. Toxins acting on potassium channels (Kv), L-type
calcium channels, acid-sensing ion channels33, cholinergic
receptors34, and others acting on platelet aggregation35 have been
reported. Nonetheless, the evidence suggests that 3FTxs, such as
MTs, fasciculins, and α-neurotoxins, coupled with presynaptic-
acting Kunitz-type proteinase inhibitor-like (dendrotoxins) could
be highly relevant for mamba venoms lethality36,37. Under an
anti-α-neurotoxin view, neutralization of these ScNtxs was
achieved for Dendroaspis angusticeps and D. polylepis, but D.
viridis lethal effect remained unaltered. These results show how
important the set of diverse neurotoxins (e.g., MTs, fasciculins,
dendrotoxins, long-chain α-neurotoxins) are to the lethality of
Dendroaspis and some Naja venoms. They also suggest that the
neutralization of the α-neurotoxins, and the possible cross-reac-
tivity, is not sufﬁcient to provide protection since mice, even
when they survived, in all cases showed envenomation symptoms.
Here, it is worth mentioning that long- and short-chain α-
neurotoxins are equally important during elapid envenomation,
and more studies are needed to decipher the pharmacokinetics
and biochemistry of each one of these neurotoxins. Also, the use
of mice as an animal model for interpreting neutralization of
venoms that are rich in short- or long-chain α-neurotoxins has to
be revised. Silva et al.38 found differential susceptibility of human
and rat nAChR to short-chain α-neurotoxins, but not to long-
chain α-neurotoxins. This ﬁnding may represent an important
challenge for the current assessment of the preclinical efﬁcacy of
antivenoms in mouse models.
Hence, further studies should take into consideration the
possible combined action among mamba toxins in order to
postulate additional antigens for immunization. Moreover, our
results promote further research in order to have a deep insight
about cross-reactivity and the variation in terms of efﬁcacy
between the different lots of EAvs against Dendroaspis venoms. In
this regard, it is important to underline that such variation was
not observed for all venoms. For instance, for the same batch of
king cobra venom (Ophiophagus hannah) and black snake
(Walterinnesia aegyptia) venom the ED50s among EAv lots were
similar. We know that these venoms are 3FTx predominant;
nonetheless, their complexity is markedly different. King cobra
venom, for example, contains LAAOs, SVMPs, and PLA2s39.
Among the rich repertoire of 3FTxs, it has been proven that long-
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chain α-neurotoxins play a key role in its lethality given the fact
that speciﬁc antibodies produced against them attenuate the
venom toxicity40,41. Importantly, other toxins, like the short-
chain α-neurotoxins, even though they are less abundant, are
substantially crucial for the venom lethality42. Our results support
this observation, as we demonstrated that O. hannah lethality can
be efﬁciently abolished by both lots of EAv, possibly by acting on
both long-chain and short-chain neurotoxins. On the other hand,
W. aegyptia venom, while less complex, is very active post-
synaptically, causing life-threatening neurotoxic envenomation43.
The most abundant toxins in this venom are short-chain α-
neurotoxins, PLA2s, and Kunitz-type proteinase inhibitor-like
proteins43,44. Nevertheless, only short-chain α-neurotoxins have
been considered as targets in the development of a new anti-
walterinnesia antivenom. For instance, the short-chain α-neuro-
toxin TIII, which is the most abundant toxin in the venom, was
used to develop an antivenom that neutralizes 50 LD50/mL44;
comparing this, 1 mL of EAv neutralizes 53 LD50s, supporting the
concept that W. aegyptia lethality is driven by its principal
components, namely short-chained α-neurotoxins. Similarly, the
most abundant and lethal component of the sea snake H. platura
(3FTx= ~50%) venom is the α-neurotoxin known as pelami-
toxin (P62388) and its proteoforms45. Owing to their high
identity to the ScNtx, both TIII and pelamitoxin are likely the
targets of the neutralizing anti-ScNtx antibodies.
To question whether the EAv could neutralize or attenuate the
lethality of elapid venoms from Oceania, we used the venom of
two genera distributed in Australia and parts of New Guinea:
Pseudechis australis, P. colleti, and Oxyuranus scutellatus. These
venoms contain short-chain neurotoxins and they are also active
at the presynaptic level like some Micrurus venoms46. None-
theless, when tested, EAv did not have any effect on their leth-
ality. Although these venoms cause neurotoxicity that leads to
respiratory arrest, our result suggest that this might be caused,
mainly, by other group of neurotoxins such as long-chain neu-
rotoxins or presynaptically acting PLA2s rather than by short-
chain neurotoxins. Alternatively, these venoms could contain
short-chain neurotoxins that are more antigenically divergent
from the consensus sequence immunogen here studied.
In conclusion, in this paper we have described the range of
efﬁcacy for a polyspeciﬁc horse-derived experimental antivenom
capable of neutralizing medically important elapid venoms dis-
tributed throughout the Americas, Africa, Middle East, and some
regions of Asia. The evidence from this study has revealed the
importance of short-chain α-neurotoxins in the lethality of sev-
eral Micrurus, Naja, Dendroaspis, Walterinnesia, Ophiophagus,
Oxyuranus, Pseudechis, and Hydrophis venoms.
Furthermore, due to the fact that snake venoms can present
intra-species variability in their composition, recombinant proteins
could be a constant source of active toxins (immunogens) for better
antidotes. For this, it is clear that further work needs to be done to
elucidate more medically relevant toxins. Correspondingly, it is
important for future research to consider variation in venoms
composition to understand how this variability could also inﬂuence
both envenomation signs and antivenom efﬁcacy47,48. The rational
concept of using a recombinant neurotoxin with “universal” con-
sensus sequence to produce a broad-speciﬁcity anti-elapid anti-
venom provides the framework for a strategy to develop either
animal-derived or recombinant antivenoms. We hope that our
research will be useful in solving the difﬁculty of conceiving alter-
native immunogens to create better therapeutic antivenoms with
higher neutralizing potencies and broader coverages.
Methods
Venoms and toxins. Venoms used in this study were from different sources.
Certiﬁed, N. melanoleuca (715.030 and 307.150), N. katiensis (code not provided),
N. oxiana (911.040), N. pallida (316.000), N. nivea (524.010), N. nubiae (101.030),
N. mossambica (505.010), N. nigricollis (105.030), N. haje (822.090), N. kaouthia
(506.000), N. atra (920.100), D. polylepis (218.020), D. angusticeps (305.00), D.
viridis (815.050), W. aegyptia (729.030), and O. hannah (923.090) venoms were
from Latoxan (Valence, France); N. nivea (NNC019) was from SA Venom Sup-
pliers (Louis Trichardt, South Africa); N. naja naja (4NN9001) from Ventoxin; the
australian venoms Oxyuranus scutellatus (OSS0319EAS, Cooktown, Australia),
P. australis (PA0319EAS, Coen Cape York, Australia), P. colleti (PC0319EAS,
Vergemont, Australia) were acquired through “La Nauyaca” (UMA INE/CITES/
DFYFS-HERP-E-0003-MOR/98, Morelos, Mexico); venoms from M. fulvius
(08.31.10) and M. tener tener (02.16.09) were from National Natural Toxins
Research Center; and venoms from M. laticollaris (two individuals), M. browni,
M. diastema (two individuals), M. distans, M. nigrocinctus (two individuals), M.
surinamensis, and sea snake H. (Pelamis) platura24 were obtained manually by
milking multiple adult snakes at the “Instituto de Biotecnología” (UNAM, Mexico,
permit SGPA/DGVS/010526/18) and “Instituto Clodomiro Picado” (UCR, Costa
Rica, permit CICUA-021-17) serpentariums.
Expression and puriﬁcation of α-neurotoxins. Stored pQE30/ScNtx10, pQE30/
MlatA149, and pQE30/r.D.H50 plasmids were transformed into Escherichia coli K-
12-derived Origami cells for expression following the same conditions as in our
previous work (for a more detailed description see de la Rosa et al.10). In short,
expressed recombinant ScNtx, MlatA1 or r.D.H were submitted to a two-step
puriﬁcation process: by Ni-NTA (Ni-nitrilotriacetic acid) afﬁnity chromatography
according to the method of polyhistidine-tagged proteins user manual (Qiagen);
and by reversed-phase high-performance liquid chromatography (RP-HPLC)
(Agilent 1100 series; Agilent, CA) loading them onto an analytical C18 column
(4.6 × 250 mm2, VYDAC®). Elution was carried out at 1 mL/min for 60 min by
applying a gradient starting at 10% of an aqueous acetonitrile solution/0.1% tri-
ﬂuoroacetic acid (TFA) and ending at 60%. Similarly, in order to isolate the α-
neurotoxin P014242 (UniProt access code) from N. melanoleuca, 2 mg of crude
venom were fractionated by RP-HPLC using a gradient toward acetonitrile solu-
tion/0.1% TFA maintaining 0% 5min, 0–15% over 10 min, 15–45% over 60 min,
45–70% over 10 min, and 70–80 over 5 min31. Finally, all identities were conﬁrmed
by mass spectrometry.
Animals. Mice strain CD-1 (18–20 g) were purchased from Harlan Mexico and
kept at animal facilities at the “Instituto de Biotecnología”, Mexico, and also, they
were provided and kept at animal facility at the “Instituto Clodomiro Picado”,
Costa Rica. Adult male horses (400–500 kg) were from Ranch “Ojo de Agua”
(Puebla, Mexico). All animals received regular veterinary supervision and were
maintained under good conditions and controlled environments. They received
water and food ad libitum. Proper animal handling, in order to minimize distress
and discomfort, was always conducted towards maximizing the animal welfare
during experimentation according to Mexican legislation for the use of laboratory
animals (Norma Oﬁcial Mexicana, 1999, NOM-062-ZOO-1999). Additionally,
internal animal handling was according to the Animal Care and Bioethics Com-
mittee at the “Instituto de Biotecnología” (ethical approval CB/IBt/Project # 254)
and “Instituto Clodomiro Picado” (ethical approval code: CICUA-021-17), which
supervised and approved all animal experiments.
Immunization, antisera collection, and sera fractionation. Three horses were
immunized by multi-site intradermal and subcutaneous route51, starting with 5 µg
and ending with 1000 µg of ScNtx per horse. The ﬁrst immunization of 5 µg was
performed in 0.5 mL phosphate-buffered saline plus 0.7 mL incomplete Freund’s
adjuvant (IFA) by intradermal route. Horses were boosted 14, 28, 42, 56, 70, 84, 98,
112, 126, 140, and 196 days later with 5, 5, 10, 20, 40, 80, 150, 300, 300, 500, 500,
and 1000 µg of the ScNtx, alternating IFA and Alum. No adjuvant was used on the
seventh and the last two immunizations. For all cases, horses were bled at weekly
intervals until day 147 and the last two blood samples were taken at days 196 and
205. Then, after a 488-day hiatus, only horse 2 was boosted four times at weekly
intervals with 300 (day 684), 500 (day 692), 1000 (day 700), and 1800 µg (day 708).
IFA and Alum were used in these ﬁrst two boosts and no adjuvants were used in
the last two; a blood sample was taken 1 week after the last immunization. Animals’
blood was allowed to clot at 37 °C for at least 2 h, chilled on ice for 1 h, and
centrifuged at 4000 × g. Serum was collected and stored frozen at −20 °C
until used.
Finally, horse immunoglobulins were obtained by caprylic (octanoic) acid
method52 described and recommended in the WHO guidelines for the production,
control, and regulation of antivenoms53. Two different lots were prepared: Lot #1
contains immunoglobulins from days 147 and 205, and Lot #2 from day 708. Each
Lot has a protein content of 50 mg/mL.
Median LD50 and ED50. Lethal potencies for toxins and whole venoms (in µg dry
weight per mouse) were determined by calculating the LD50, which is deﬁned as the
amount of venom that produces the death of 50% of the mice challenged. Brieﬂy,
ﬁve mice per group were injected by IV route and the LD50 was obtained from the
plot analysis of mice mortality (at 24 h after injection) vs. toxin or venom dose
used. The LD50 was expressed in µg/mouse. For neutralization experiments, 3 ×
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LD50 of either toxin or whole venom were pre-incubated 30 min at 37 °C with
varying volumes of antiserum and then injected by IV route. After 24 h, median
effective dose (ED50) was calculated from the plot of survival percent (at 48 h) vs.
antiserum dose, and it is deﬁned as the volume of antiserum able to protect 50% of
the mice challenged (ﬁve mice per group)19. Only for the native type I α-
neurotoxin P014242, N. haje and Oxyuranus scutellatus, due to their high toxicity,
5 × LD50 of each were used for ED50 calculation. Control groups tested without
antiserum or with pre-immune horse sera always resulted in 100% mortality;
likewise, 400 μL (50 mg/mL) of puriﬁed horse pre-immune immunoglobulins
showed no alterations in the envenomation process and mortality. The ED50 was
expressed in microliters. Prism (GraphPad Inc., San Diego, CA) was used to cal-
culate the data by non-linear regression. Experiments were carried out following
the guidelines published by WHO involved in the production, control, and reg-
ulation of venoms and antivenoms54.
Antiserum titration. Each horse hyperimmune serum was tested by ELISA for the
presence of speciﬁc antibodies against the ScNtx. Flat- bottom, 96-MicroWell™
polystyrene microtiter plates (Maxisorp Nunc) were coated with 100 μL/well of
5 μg/mL ScNtx in carbonate/bicarbonate stock solution at pH 9.5 and incubated
overnight at 4 °C. After incubation, plates were rinsed three times with 200 μL/well
of rinsing buffer (50 mM Tris-HCl, 150 mM NaCl, 0.05% Tween-20, and pH 8).
After that, it was added 150 μL/well of blocking buffer (50 mM Tris-HCl, 5 mg/mL
gelatin, 0.2% Tween-20, and pH 8) and incubated 2 h at 37 °C. After a second
rinsing cycle, serum anti-ScNtx (1:30 dilution) was mixed with vehicle buffer
(50 mM Tris-HCl, 0.5 M NaCl, 1 mg/mL gelatin, 0.05% Tween-20, and pH 8), and
placed in the ﬁrst well (200 μL) and further serially diluted 1:3 (with the same
buffer of the ELISA plates) from wells 2 to 11, while well 12 contained only vehicle
buffer. Plates were incubated for 1 h at 37 °C, and after rinsing twice; plates were
incubated with 100 μL/well of peroxidase-conjugated rabbit anti-horse immu-
noglobulins (5 × 10−4 μg/mL, Rockland) for 1 h at 37 °C. Plates were then rinsed
three times with rinsing buffer and, ﬁnally, 100 μL/well of peroxidase chromogenic
substrate (soluble BM Blue POD substrate, Roche) were added, and incubated for
10 min at room temperature, in darkness. At the end of the incubation, the reaction
was stopped with 100 μL/well sodium dodecyl sulfate 5%. The absorbance of the
plates was read at 450 nm and the results were plotted using Prism 4.0 graphic
package with non-linear analysis of regression51.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
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Additional information is available from the corresponding author(s) upon request.
Received: 26 November 2018 Accepted: 23 July 2019
References
1. Kasturiratne, A. et al. The global burden of snakebite: a literature analysis and
modelling based on regional estimates of envenoming and deaths. PLoS Med.
5, e218 (2008).
2. Scheske, L., Ruitenberg, J. & Bissumbhar, B. Needs and availability of snake
antivenoms: relevance and application of international guidelines. Int. J.
Health Policy Manag. 4, 447–457 (2015).
3. Gutiérrez, J. M., León, G., Lomonte, B. & Angulo, Y. Antivenoms for snakebite
envenomings. Inﬂamm. Allergy Drug Targets 10, 369–380 (2011).
4. Fernández, J. et al. Venomic and antivenomic analyses of the Central
American coral snake, Micrurus nigrocinctus (Elapidae). J. Proteome Res. 10,
1816–1827 (2011).
5. Laustsen, A. H., Lomonte, B., Lohse, B., Fernández, J. & Gutiérrez, J. M.
Unveiling the nature of black mamba (Dendroaspis polylepis) venom through
venomics and antivenom immunoproﬁling: Identiﬁcation of key toxin targets
for antivenom development. J. Proteom. 119, 126–142 (2015).
6. Sells, P. G., Jones, R. G. A., Laing, G. D., Smith, D. C. & Theakston, R. D. G.
Experimental evaluation of ovine antisera to Thai cobra (Naja kaouthia)
venom and its α-neurotoxin. Toxicon 32, 1657–1665 (1994).
7. Barber, C. M., Isbister, G. K. & Hodgson, W. C. Alpha neurotoxins. Toxicon
66, 47–58 (2013).
8. Ranawaka, U. K., Lalloo, D. G. & de Silva, H. J. Neurotoxicity in snakebite—
the limits of our knowledge. PLoS Negl. Trop. Dis. 7, e2302 (2013).
9. Silva, A., Hodgson, W. C. & Isbister, G. K. Antivenom for neuromuscular
paralysis resulting from snake envenoming. Toxins (Basel) 9, 143 (2017).
10. de la Rosa, G., Corrales-García, L. L., Rodriguez-Ruiz, X., López-Vera, E. &
Corzo, G. Short-chain consensus alpha-neurotoxin: a synthetic 60-mer
peptide with generic traits and enhanced immunogenic properties. Amino
Acids 50, 885–895 (2018).
11. Laustsen, A. H., Lohse, B., Lomonte, B., Engmark, M. & Gutiérrez, J. M.
Selecting key toxins for focused development of elapid snake antivenoms and
inhibitors guided by a Toxicity Score. Toxicon 104, 43–45 (2015).
12. Maeda, N. & Tamiya, N. Three neurotoxins from the venom of a sea snake
Astrotia stokesii, including two long-chain neurotoxic proteins with amidated
C -termini. Biochem. J. 175, 507–517 (1978).
13. Engmark, M. et al. High-throughput immuno-proﬁling of mamba
(Dendroaspis) venom toxin epitopes using high-density peptide microarrays.
Sci. Rep. 6, 36629 (2016).
14. Chang, L.-S., Lin, J., Kuo, K.-W., Lin, S.-R. & Chang, C.-C. Characterization of
epitopes in native and unfolded cobrotoxin: evidence of an immunodominant
C-terminal region related to the production of precipitating and non-
precipitating antibodies against cobrotoxin1. J. Biochem. 118, 686–692 (1995).
15. Menez, A. et al. Comparison of the “toxic” and antigenic regions in toxin α
isolated from Naja nigricollis venom. Toxicon 20, 95–103 (1982).
16. Engmark, M., Jespersen, M. C., Lomonte, B., Lund, O. & Laustsen, A. H. High-
density peptide microarray exploration of the antibody response in a
rabbit immunized with a neurotoxic venom fraction. Toxicon 138, 151–158
(2017).
17. Lomonte, B. et al. Venoms of Micrurus coral snakes: evolutionary trends in
compositional patterns emerging from proteomic analyses. Toxicon 122, 7–25
(2016).
18. Vergara, I. et al. Eastern coral snakeMicrurus fulvius venom toxicity in mice is
mainly determined by neurotoxic phospholipases A2. J. Proteom. 105,
295–306 (2014).
19. de Roodt, A. R. et al. Effectiveness of two common antivenoms for North,
Central, and South American Micrurus envenomations. J. Toxicol. Clin.
Toxicol. 42, 171–178 (2004).
20. Olamendi-Portugal, T. et al. Proteomic analysis of the venom from the ﬁsh
eating coral snake Micrurus surinamensis: novel toxins, their function and
phylogeny. Proteomics 8, 1919–1932 (2008).
21. Tasoulis, T. & Isbister, G. A review and database of snake venom proteomes.
Toxins (Basel). 9, 290 (2017).
22. Petras, D. et al. Snake venomics of African spitting cobras: toxin composition
and assessment of congeneric cross-reactivity of the pan-African EchiTAb-
Plus-ICP antivenom by antivenomics and neutralization approaches. J.
Proteome Res. 10, 1266–1280 (2011).
23. Calvete, J., Sanz, L., Pla, D., Lomonte, B. & Gutiérrez, J. Omics meets biology:
application to the design and preclinical assessment of antivenoms. Toxins
(Basel). 6, 3388–3405 (2014).
24. Malih, I. et al. Proteomic analysis of Moroccan cobra Naja haje legionis venom
using tandem mass spectrometry. J. Proteom. 96, 240–252 (2014).
25. Ramos-Cerrillo, B. et al. Characterization of a new polyvalent antivenom
(Antivipmyn Africa) against African vipers and elapids. Toxicon 52, 881–888
(2008).
26. Lauridsen, L. P., Laustsen, A. H., Lomonte, B. & Gutiérrez, J. M. Exploring the
venom of the forest cobra snake: toxicovenomics and antivenom proﬁling of
Naja melanoleuca. J. Proteom. 150, 98–108 (2017).
27. Dutta, S. et al. Proteomic analysis to unravel the complex venom proteome of
eastern India Naja naja: correlation of venom composition with its
biochemical and pharmacological properties. J. Proteom. 156, 29–39
(2017).
28. Arnberg, H., Eaker, D., Fryklund, L. & Karlsson, E. Amino acid sequence of
oxiana α, the main neurotoxin of the venom of Naja naja oxiana. Biochim.
Biophys. Acta 359, 222–232 (1974).
29. Kao, P.-H., Lin, S.-R. & Chang, L.-S. Interaction of Naja naja atra cardiotoxin
3 with H-trisaccharide modulates its hemolytic activity and membrane-
damaging activity. Toxicon 55, 1387–1395 (2010).
30. Kﬁr, R., Botes, D. P. & Osthoff, G. Preparation and characterization of
monoclonal antibody speciﬁc for naja nivea cardiotoxin VIII from the Naja
and Hemachatus genera of the Elapidae family (SLOTTA and VICK, 1969;
cardiotoxin peptide chain consists of 60–61 amino acids, cross-link. Toxicon
23, 135–144 (1985).
31. Shan, L.-L. et al. Proteomic characterization and comparison of venoms from
two elapid snakes (Bungarus multicinctus and Naja atra) from China. J.
Proteom. 138, 83–94 (2016).
32. Petras, D., Heiss, P., Harrison, R. A., Süssmuth, R. D. & Calvete, J. J. Top-
down venomics of the East African green mamba, Dendroaspis angusticeps,
and the black mamba, Dendroaspis polylepis, highlight the complexity of their
toxin arsenals. J. Proteom. 146, 148–164 (2016).
33. Mourier, G. et al. Mambalgin-1 pain-relieving peptide, stepwise solid-phase
synthesis, crystal structure, and functional domain for acid-sensing ion
channel 1a inhibition. J. Biol. Chem. 291, 2616–2629 (2016).
34. Fruchart-Gaillard, C. et al. Engineering of three-ﬁnger fold toxins creates
ligands with original pharmacological proﬁles for muscarinic and adrenergic
receptors. PLoS ONE 7, e39166 (2012).
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-11639-2 ARTICLE
NATURE COMMUNICATIONS |         (2019) 10:3642 | https://doi.org/10.1038/s41467-019-11639-2 | www.nature.com/naturecommunications 7
35. Oyama, E. & Takahashi, H. Puriﬁcation and characterization of two platelet-
aggregation inhibitors, named angustatin and H-toxin TA2, from the venom
of Dendroaspis angusticeps. Toxicon 93, 61–67 (2015).
36. Blanchet, G. et al. Polypharmacology proﬁles and phylogenetic analysis of
three-ﬁnger toxins from mamba venom: case of aminergic toxins. Biochimie
103, 109–117 (2014).
37. Servent, D. et al. Muscarinic toxins. Toxicon 58, 455–463 (2011).
38. Silva, A., Cristofori-Armstrong, B., Rash, L. D., Hodgson, W. C. & Isbister, G.
K. Deﬁning the role of post-synaptic α-neurotoxins in paralysis due to snake
envenoming in humans. Cell. Mol. Life Sci. 75, 4465–4478 (2018).
39. Vonk, F. J. et al. The king cobra genome reveals dynamic gene evolution and
adaptation in the snake venom system. Proc. Natl Acad. Sci. USA 110,
20651–20656 (2013).
40. Danpaiboon, W. et al. Ophiophagus hannah venom: proteome, components
bound by Naja kaouthia antivenin and neutralization by N. kaouthia
neurotoxin-speciﬁc human ScFv. Toxins (Basel). 6, 1526–1558 (2014).
41. de la Rosa, G., Pastor, N., Alagón, A. & Corzo, G. Synthetic peptide antigens
derived from long-chain alpha-neurotoxins: immunogenicity effect against
elapid venoms. Peptides 88, 80–86 (2017).
42. Gowtham, Y. J., Mahadeswaraswamy, Y. H., Girish, K. S. & K, K. Cross-
reactivity and neutralization of Indian King cobra (Ophiophagus hannah)
venom by polyvalent and monovalent antivenoms. Int. Immunopharmacol.
21, 148–155 (2014).
43. Ismail, M., Abd-Elsalam, M. A. & Al-Ahaidib, M. S. Pharmacokinetics of 125I-
labelled Walterinnesia aegyptia venom and its speciﬁc antivenins: ﬂash
absorption and distribution of the venom and its toxin versus slow absorption
and distribution of IgG, F(ab′)2 and F(ab) of the antivenin. Toxicon 36,
93–114 (1998).
44. Ismail, M., Al-Ahaidib, M. S., Abdoon, N. & Abd-Elsalam, M. A. Preparation
of a novel antivenom against Atractaspis and Walterinnesia venoms. Toxicon
49, 8–18 (2007).
45. Lomonte, B. et al. Two color morphs of the pelagic yellow-bellied sea snake,
Pelamis platura, from different locations of Costa Rica: snake venomics,
toxicity, and neutralization by antivenom. J. Proteom. 103, 137–152 (2014).
46. Silva, A., Hodgson, W. & Isbister, G. Cross-neutralisation of in vitro
neurotoxicity of asian and australian snake neurotoxins and venoms by
different antivenoms. Toxins (Basel). 8, 302 (2016).
47. Chippaux, J.-P., Williams, V. & White, J. Snake venom variability: methods of
study, results and interpretation. Toxicon 29, 1279–1303 (1991).
48. de Roodt, A. R., Lanari, L. C., Costa de Oliveira, V., Laskowicz, R. D. & Stock,
R. P. Neutralization of Bothrops alternatus regional venom pools and
individual venoms by antivenom: a systematic comparison. Toxicon 57,
1073–1080 (2011).
49. Clement, H. et al. Heterologous expression, protein folding and antibody
recognition of a neurotoxin from the Mexican coral snake Micrurus
laticorallis. J. Venom. Anim. Toxins Incl. Trop. Dis. 22, 25 (2016).
50. Guerrero-Garzón, J. F. et al. Cloning and sequencing of three-ﬁnger toxins
from the venom glands of four Micrurus species from Mexico and
heterologous expression of an alpha-neurotoxin from Micrurus diastema.
Biochimie 147, 114–121 (2018).
51. de la Rosa, G., Olvera, F., Cruz, E., Paniagua, D. & Corzo, G. Use of irradiated
elapid and viperid venoms for antivenom production in small and large
animals. Toxicon 155, 32–37 (2018).
52. Rojas, G., Jiménez, J. & Gutiérrez, J. Caprylic acid fractionation of
hyperimmune horse plasma: description of a simple procedure for antivenom
production. Toxicon 32, 351–363 (1994).
53. Chippaux, J.-P. Guidelines for the production, control and regulation of snake
antivenom immunoglobulins. Biol. Aujourd’hui. 204, 87–91 (2010).
54. WHO. Progress in the characterization of venoms and standardization of
antivenoms. WHO offset Publ. https://doi.org/10.1016/0041-0101(81)90095-7,
1–44 (1981).
Acknowledgements
We acknowledge Ricardo Mondragon, M. en C. Alejandro Olvera, M. en Biotec. Herlinda
Clement, Dr. Bradley Yates, and personal from “Ojo de Agua” Ranch and Instituto
Clodomiro Picado for providing technical support. This work received funding from the
Direccion General de Asuntos del Personal Academico (DGAPA-UNAM) grant number
IN203118 awarded to G.C. and IN207218 awarded to A.A. Partial ﬁnancial support by
Vicerrectoria de investigacion, Universidad de Costa Rica (VI-B7608), awarded to B.L. is
gratefully acknowledged.
Author contributions
G.d.l.R. performed Lot #1 and the other experiments and wrote the manuscript. I.G.A.
performed the second Lot #2 of experiments. F.O. performed the puriﬁcation of IgGs.
A.A. and B.L. contributed to the study concept, design, and sample acquisition. G.d.l.R.
and G.C. conceived and designed the project. G.C. served as principal investigator. All
authors discussed the results, contributed to critical revisions, and approved the ﬁnal
manuscript.
Additional information
Supplementary Information accompanies this paper at https://doi.org/10.1038/s41467-
019-11639-2.
Competing interests: The authors declare no competing interests.
Reprints and permission information is available online at http://npg.nature.com/
reprintsandpermissions/
Peer review information: Nature Communications would like to thank Andreas Laustsen
and other, anonymous, reviewers for their contributions to the peer review of this work.
Peer reviews reports are available.
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional afﬁliations.
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made. The images or other third party
material in this article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not included in the
article’s Creative Commons license and your intended use is not permitted by statutory
regulation or exceeds the permitted use, you will need to obtain permission directly from
the copyright holder. To view a copy of this license, visit http://creativecommons.org/
licenses/by/4.0/.
© The Author(s) 2019
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-11639-2
8 NATURE COMMUNICATIONS |         (2019) 10:3642 | https://doi.org/10.1038/s41467-019-11639-2 | www.nature.com/naturecommunications
